Skip to main content

Table 1 Characteristics of healthy controls (HC) and AS patients

From: Down-regulated miR-495 can target programmed cell death 10 in ankylosing spondylitis

Characteristics

AS (N = 150)

HC (N = 150)

Gender (Male/Female)

Male (N = 114)

Female (N = 36)

Male (N = 114)

Female (N = 36)

Age (years)

M: 34.0 ± 12.5

F: 32.5 ± 10.5

M: 35.5 ± 10.5

F: 33.5 ± 8.5

Disease duration (years), mean ± SD

5.5 ± 0.8

0

HLA-B27, mean ± SD (0~147)

161.0 ± 8.5

Normal

ESR (mm/h), mean ± SD (0~15 for Male; 0~20 for Female)

22.5 ± 11.9

Normal

CRP (mg/dL), mean ± SD (1~15)

0.82 ± 0.54

Normal

BASDAI, mean ± SD

4.43 ± 1.35

Normal

BASFI, mean ± SD

36.8 ± 19.6

Normal

mSASSS

13.0 ± 7.0

Normal

Suggestions for immunosuppressant drugs

 Steroids

4%

0

 DMARDs

6%

0

 NSAIDs

100%

0

  1. AS, ankylosing spondylitis; HC, healthy control; SD, Standard Deviation; HLA-B27, Human Leukocyte Antigen (HLA) B27; ESR, Erythrocyte Sedimentation Rate; CRP, C Reactive Protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity; BASFI, Bath Ankylosing Spondylitis Functionality Index; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; DMARDs, Disease-Modifying Anti-Rheumatic Drugs; NSAIDs, Non-Steroidal Anti-Inflammatory Drugs